Browse by Audience
Skip to content
Papers of the Week
Intratumoral administration of CD1c (BDCA-1) and CD141 (BDCA-3) myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial.
Abstract
Intratumoral (IT) myeloid dendritic cells (myDCs) play a pivotal role in initiating antitumor immune responses and relicensing of anti-tumor cytotoxic T lymphocytes within the tumor microenvironment. Talimogene laherparepvec (T-VEC) induces immunogenic cell death, thereby providing maturation signals and enhancing the release of tumor antigens that can be captured and processed by CD1c (BDCA-1) / CD141 (BDCA-3) myDCs, in order to reinvigorate the cancer-immunity cycle.